Immunic Pushes Boundaries in MS with Vidofludimus
Shaking Things Up in Multiple Sclerosis Therapy There's no telling how often the biotech sector tosses around the term 'game-changer,' but when Immunic's name comes up, more ears are perking up these days. The New York-based firm, waving the Nasdaq: IMUX flag, is lining up a virtual shindig come September 9, 2026, and for anyone invested in multiple sclerosis (MS) or...
Continue Reading